#Germany #medical technology #stent #Putzbrunn #GORE® VIABAHN®

GORE® VIABAHN® FORTEGRA Venous Stent Receives CE Mark Approval

In a significant advancement for vascular care, W. L. Gore & Associates Medical Products has announced that its GORE® VIABAHN® FORTEGRA Venous Stent has received CE Mark approval. This news is pivotal for physicians and patients who are seeking effective treatment options for symptomatic inferior vena cava (IVC) obstruction and iliofemoral venous flow issues. Having already gained clearance from the U.S. FDA, this CE mark reflects Gore's dedication to expanding access to this innovative stenting solution worldwide.

The FORTEGRA stent, part of the well-regarded VIABAHN® device family, is tailor-made for patients suffering from deep vein disease. The stent boasts a unique open structure, self-expanding nitinol framework, and a polymer mesh, all designed to provide unmatched adaptability, strength, and durability. This cutting-edge technology strikes a perfect balance between flexibility and compression resistance, ensuring that the stent adapts to a patient's natural anatomy while maintaining effective venous flow.

Clinical Significance

The GORE® VIABAHN® FORTEGRA Venous Stent is not merely a product; it represents a major breakthrough in treating complex venous obstructions. Professor Stephen Black, a renowned venous surgery expert at Guy's and St Thomas' Hospital in London, emphasized that the FORTEGRA stent specifically addresses the difficulties posed by inferior vena cava obstructions and iliofemoral blockages, aiding in the preservation of essential blood flow dynamics. The stent's design caters specifically to the unique anatomical challenges faced by patients, offering a solution honed for optimal clinical outcomes.

Research surrounding the FORTEGRA stent was conducted as part of a landmark prospective trial—the first to include evaluations of the IVC along with iliofemoral veins. Results from the study have been impressive, showing that 81% of patients who reported pain at the study's initiation experienced significant pain relief within 12 months, alongside a notable decrease in pain scoring. The stent's primary patency rates were also strong, maintaining at 83.4% after a year with no serious safety concerns related to the device.

Moreover, the study demonstrated significant improvements in quality-of-life metrics as assessed by validated instruments such as VEINES-QOL and EQ-5D-5L. Financially, the continued success of the FORTEGRA stent highlights not just clinical effectiveness but also enhanced patient well-being and decreased need for further medical interventions, offering healthcare providers sustainable long-term value.

A Legacy of Transformative Medical Technologies

With over 55 million medical devices implanted globally in the last 50 years, Gore's commitment to improving patient outcomes through innovation is well established. The performance, ease of use, and quality service associated with Gore products are notable components of the value proposition they extend to physicians, healthcare facilities, and insurers alike.

The GORE® VIABAHN® FORTEGRA is a testament to Gore's extensive research efforts and dedication to medical excellence, combining transformative technology with quality assurance that has set industry benchmarks. Gore remains committed to collaborating with healthcare professionals worldwide, continuously working to enhance clinical outcomes through superior technology and education. For more information on the GORE® VIABAHN® FORTEGRA, visit goremedical.com.

In conclusion, as medical technology continues to evolve, the advent of the FORTEGRA stent marks a critical milestone in the treatment of venous disease, setting a high standard for innovation and patient-centered care in the vascular domain.